Earlier this year, CMS created a new reimbursement code (Q2024) for physicians who use smaller doses of Bevacizumab (Avastin) to treat AMD. We were pleased to learn that CMS recognized that its billing changes for smaller doses of the drug had unintended consequences, and has decided to permit ophthalmologists to revert back to use of the previous reimbursement code that correctly takes into account the compounding costs of smaller doses of Avastin. Unfortunately, CMS' solution is not scheduled to be implemented until Jan. 1, 2010, and will not correct the huge impact its initial decision has already had. In the interest of AMD patients, the Academy, the American Society of Retina Specialists, the Macula Society and the Retina Society are enlisting Congress’ participation to urge CMS to apply the correction retroactively, to Oct. 1.